Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Podcast: Woodford’s UK Biotech Fallout, Rare Disease Deals and Brexit

The Low-Down On Big Biopharma Stories

Executive Summary

Scrip's Kevin Grogan and Andrew McConaghie try out the padded cell/recording studio at Informa HQ in London, giving their take on three hot topics from biopharma and healthcare.

A pilot edition podcast from Scrip’s Kevin Grogan and Andrew McConaghie, with a special focus on developments in UK and European biopharma and healthcare.

 

Scrip Podcast

Pilot episode

 

 

Woodford's biotech fallout, rare disease deals, Brexit

 

Covering the fall of former star fund manager Neil Woodford, analysis of a recent spate of big licensing deals in the rare disease space, plus insights on what Brexit will mean for the UK life sciences sector in the long term.
 
Please give us feedback on this pilot episode – any comments on guests to invite or topics to cover gratefully received. Email andrew.mcconaghie@informa.com kevin.grogan@informa.com

Topics

UsernamePublicRestriction

Register

SC126067

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel